Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
CAMBRIDGE, Mass., May 02, 2018 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2018 financial results on Wednesday, May 9, 2018. Jounce Therapeutics' management team will host a live conference call and webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.
Conference Call and Webcast
To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 3760478. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Komal Joshi
Jounce Therapeutics, Inc.
(857) 320-2523
[email protected]
